Drugs / Valproate
Valproate
also known as
sodium valproate · VPA · valproic acid · magnesium valproate · DEP · Depacon · Depakine · Depakine chrono · +5 more
Small molecule targets GSK3B, SMN2 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DEPACON | — | 2002-01-24 | fda.gov ↗ |
| Approved | US (FDA) | DEPACON | — | 1996-12-30 | fda.gov ↗ |
Trials 69 · started per year
today
US approved 1996
1
1
1
1
2
5
5
5
3
3
3
1
2
2
4
3
3
2
5
1
4
4
3
1
2
1
19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05017454 | May 2021 → Jan 2023 | alopecia areata | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02144623 | Jan 2015 → Feb 2016 | B-cell chronic lymphocytic leukemia | Lund University Hospital | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06211283 | Sep → Oct 2023 | — | Desitin Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03681158 | Oct 2018 → Apr 2019 | epilepsy | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02648633 | May 2016 → Feb 2017 | glioblastoma | University of Virginia | Terminated | No outcome recorded |
| Phase 1 | NCT01495104 | Oct 2011 → Jan 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00513162 | Jul 2007 → Sep 2012 | metastatic malignant neoplasm in the brain | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07226141 | Jan 2026 → Sep 2027 expected | ametropic amblyopia, strabismus | Boston Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05920512 | Apr 2022 → Apr 2025 | hemophilia | Xue-chun Lu | Unknown | No outcome recorded |
| Phase 1/2 | NCT03825250 | Nov 2018 → Oct 2024 | coronary artery disorder, heart valve disorder, multiple organ dysfunction syndrome | University of Leicester | Unknown | No outcome recorded |
| Phase 1/2 | NCT03616223 | Jul → Dec 2018 | sensorineural hearing loss disorder | Frequency Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02899611 | Aug 2016 → Jun 2021 | epilepsy | Cerebral Therapeutics LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01622439 | Jun 2012 → Mar 2018 | diffuse large B-cell lymphoma | Lund University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00240110 | Mar 2006 → Mar 2014 | bipolar disorder, cocaine dependence | University of Miami | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07487675 | Sep 2024 → May 2025 overdue | temporomandibular joint disorder | Tanta University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05694936 | Jan 2023 → Jan 2026 overdue | colorectal cancer | Australasian Gastro-Intestinal Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05224531 | May 2022 → Aug 2024 | pulmonary arterial hypertension | Cereno Scientific AB | Completed | No outcome recorded |
| Phase 2 | NCT04997811 | Dec 2021 → Jan 2025 | myelodysplastic syndrome | Prof. Janet Dunn | Unknown | No outcome recorded |
| Phase 2 | NCT04940572 | Nov 2021 → Nov 2025 | Wolfram syndrome | Centre d'Etude des Cellules Souches | Unknown | No outcome recorded |
| Phase 2 | NCT03717909 | Dec 2018 → Nov 2024 | Wolfram syndrome | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03025906 | Feb 2017 → Oct 2019 | epilepsy with generalized tonic-clonic seizures | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 2 | NCT01730313 | Feb 2016 → Jul 2017 | — | Centers for Disease Control and Prevention | Withdrawn | No outcome recorded |
| Phase 2 | NCT03112889 | Jan 2015 → Apr 2017 | glycogen storage disease V | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT01619644 | Apr 2012 → Sep 2014 | Rubinstein-Taybi syndrome | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 2 | NCT00634205 | Jul 2006 → Mar 2009 | malignant mesothelioma | European Lung Cancer Working Party | Completed | No outcome recorded |
| Phase 2 | NCT00404508 | Sep 2005 → Oct 2006 | refractory malignant neoplasm | National Institute of Cancerology | Completed | No outcome recorded |
| Phase 2 | NCT00404326 | May 2005 → Nov 2006 | cervical cancer | National Institute of Cancerology | Completed | No outcome recorded |
| Phase 2 | NCT00206778 | Jul 2003 → Jul 2007 | manic bipolar affective disorder | Beth Israel Medical Center | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05431595 | Jul 2022 → Feb 2027 expected | delirium, epilepsy | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02265770 | Jun 2015 → Jun 2028 expected | childhood ependymoma | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00221637 | Mar 2002 → Jul 2005 | neuralgia, neuropathy, painful | University Hospital, Bordeaux | Terminated | No outcome recorded Stop: Enrollment |
| Phase 39 trials · 2 missed | ||||||
| Phase 3 | NCT00533299 | Aug 2007 → Dec 2009 | ovarian cancer | National Institute of Cancerology | Unknown | No outcome recorded |
| Phase 3 | NCT00447369 | May 2007 → Mar 2008 | migraine disorder | Hospital Militar del General Luis Felipe Brieba Aran | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT00136110 | Apr 2005 → Feb 2007 | amyotrophic lateral sclerosis | UMC Utrecht | Completed | Missed primary |
| Phase 3 | NCT00071721 | Oct 2003 → Feb 2009 | Alzheimer disease | Alzheimer's Disease Cooperative Study (ADCS) | Completed | Missed primary |
| Phase 3 | NCT00057681 | Feb 2003 → Dec 2008 | bipolar disorder | Washington University School of Medicine | Completed | Mixed |
| Phase 3 | NCT00254774 | Jan 2002 → Mar 2006 | bipolar disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00236717 | Sep 1997 → Nov 2000 | epilepsy | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00004817 | Feb 1991 → ? | brain injury, post-traumatic epilepsy | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT00065884 | — | autism | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 418 trials · 1 met primary | ||||||
| Phase 4 | NCT06081283 | Nov 2023 → Dec 2024 | brain hypoxia - ischemia, cardiac arrest, intracerebral hemorrhage, traumatic brain injury | University of North Carolina, Chapel Hill | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT07046676 | Dec 2022 → Dec 2025 overdue | epilepsy | The First Affiliated Hospital of University of South China | Recruiting | No outcome recorded |
| Phase 4 | NCT03689114 | May 2021 → Jun 2024 | focal epilepsy | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT03652974 | Sep 2018 → Aug 2021 | schizophrenia | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT03235531 | Jul 2017 → Jul 2019 | alcohol abuse, alcohol dependence, alcohol withdrawal | CAMC Health System | Unknown | No outcome recorded |
| Phase 4 | NCT01893229 | Sep 2013 → Dec 2015 | bipolar disorder | Guiyun Xu | Unknown | No outcome recorded |
| Phase 4 | NCT02011750 | Apr 2013 → Oct 2017 | schizophrenia, toxoplasmosis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT01083784 | Mar 2010 → Dec 2012 | cardiac arrest | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00794625 | Nov 2008 → Nov 2012 | attention deficit-hyperactivity disorder | Joseph Blader | Unknown | Met primary |
| Phase 4 | NCT00807989 | Mar 2008 → May 2012 | epilepsy | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01000402 | Feb 2008 → Oct 2012 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 4 | NCT00385411 | Mar 2006 → Oct 2008 | epilepsy | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00139074 | Jul 2005 → Jun 2006 | bipolar disorder | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00194025 | Nov 2004 → Nov 2006 | schizophrenia | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00137709 | Nov 2004 → Jul 2008 | epilepsy | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT00264173 | Feb 2004 → Sep 2006 | bipolar disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00367874 | Feb → Nov 2003 | opiate dependence, substance withdrawal syndrome | Sorlandet Hospital HF | Completed | No outcome recorded |
| Phase 4 | NCT00153270 | Sep 2000 → Apr 2001 | asthma | Centre of Chinese Medicine, Georgia | Completed | No outcome recorded |
| Phase not applicable10 trials · 2 missed | ||||||
| — | NCT06549426 | Apr 2025 → Dec 2029 expected | epilepsy | University of Twente | Recruiting | No outcome recorded |
| — | NCT04218981 | Jan 2020 → Jun 2023 | mental disorder | Central South University | Completed | No outcome recorded |
| — | NCT02556320 | May 2013 → Aug 2015 | drug allergy, epilepsy | University Hospital, Rouen | Completed | No outcome recorded |
| — | NCT01791868 | Feb 2013 → Jul 2018 | epilepsy with generalized tonic-clonic seizures | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| — | NCT01463111 | May 2011 → Apr 2016 | bipolar disorder | Emory University | Completed | No outcome recorded |
| — | NCT00570219 | Feb 2005 → May 2008 | substance withdrawal syndrome | University of Helsinki | Completed | No outcome recorded |
| — | NCT00167934 | Dec 2004 → Dec 2008 | schizophrenia | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00159588 | Jan 2004 → Nov 2006 | headache disorder | Norwegian University of Science and Technology | Completed | Missed primary |
| — | NCT00203242 | Jul 2003 → Sep 2006 | cluster headache syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| — | NCT00012558 | Sep 1998 → Sep 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | Mixed |
| Comparator or background therapy38 trials | ||||||
| Phase 1 | NCT05181007 Comparator | Dec 2021 → Mar 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03903302 Comparator | Oct 2017 → Feb 2018 | thrombotic disease | Cereno Scientific AB | Completed | No outcome recorded |
| Phase 2 | NCT02625779 Comparator | Mar 2016 → Apr 2017 | bipolar depression | Ewha Womans University Mokdong Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01543139 Comparator | Dec 2015 → Apr 2017 | bipolar depression | Ewha Womans University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02920060 Comparator | Jan 2015 → Jul 2016 | epilepsy with generalized tonic-clonic seizures | Banaras Hindu University | Completed | No outcome recorded |
| Phase 2 | NCT00000439 Comparator | Oct 2000 → Aug 2003 | alcohol dependence, bipolar disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 3 | NCT06929273 Background | Jul 2025 → Jun 2028 expected | bipolar I disorder | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT05722951 Background | Oct 2022 → Jun 2024 | epilepsy | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04274179 Comparator | Aug 2020 → May 2028 expected | childhood absence epilepsy | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT04698525 Comparator | Feb 2019 → Jan 2020 | migraine disorder | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 3 | NCT01671384 Comparator | Aug 2013 → Dec 2016 | spinal muscular atrophy | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03039842 Comparator | Jan 2013 → Dec 2016 | bipolar II disorder | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01750541 Comparator | Dec 2012 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01342549 Comparator | Sep 2011 → Jun 2015 | alcohol dependence | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT00857584 Background | May 2009 → Feb 2011 | bipolar depression | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00665366 Comparator | Jun 2008 → Oct 2011 | manic bipolar affective disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01188265 Background | Jun 2007 → Dec 2010 | bipolar disorder | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00266630 Background | Nov 2005 → May 2009 | manic bipolar affective disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00175903 Comparator | Feb 2005 → Oct 2007 | epilepsy | UCB Pharma | Completed | Missed primary |
| Phase 3 | NCT00221403 Comparator | Sep 2004 → May 2011 | bipolar I disorder | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT01977300 Background | Jan 2003 → Aug 2011 | bipolar I disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT05881928 Background | Jul 2024 overdue | epilepsy | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04513314 Comparator | Mar 2023 | COVID-19, delirium, viral pneumonia | University of Miami | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06089356 Comparator | Jan 2023 → Jan 2024 | migraine disorder | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT05481957 Comparator | Mar 2022 → Jun 2023 | bipolar depression | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT03490487 Background | Jun 2018 → Dec 2020 | self-limited epilepsy with centrotemporal spikes | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03940326 Comparator | Apr 2018 → Oct 2019 | epilepsy with generalized tonic-clonic seizures | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02205931 Comparator | Jan 2015 → Jun 2018 | epilepsy | University College, London | Unknown | No outcome recorded |
| Phase 4 | NCT01267864 Comparator | Nov 2010 → Mar 2013 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00713622 Comparator | Jun → Dec 2008 | epilepsy | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00484471 Background | Oct 2007 → Nov 2011 | bipolar disorder | Korea Otsuka International Asia Arab | Completed | No outcome recorded |
| Phase 4 | NCT00261443 Background | Sep 2005 → Jun 2009 | bipolar disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Met primary |
| — | NCT03636958 Background | Feb 2021 → Jul 2025 | epilepsy | Assistance Publique Hopitaux De Marseille | Withdrawn | No outcome recorded |
| — | NCT02926976 Comparator | Nov 2016 → Sep 2019 | schizophrenia | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT00774306 Comparator | Apr 2009 → Jun 2012 | subarachnoid hemorrhage | Thomas Jefferson University | Terminated | No outcome recorded |
| — | NCT00742638 Comparator | Mar 2008 → May 2010 | bipolar disorder | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT00552500 Comparator | Feb 2003 → Dec 2005 | — | Washington University School of Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2020-03-10 | Cereno Scientific AB | Regulatory Cereno Scientific Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension cerenoscientific.com ↗
Cereno Scientific today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s lead compound CS1, for the treatment of Pulmonary Arterial Hypertension (PAH). |
| 2019-07-29 | Cereno Scientific AB | Results Article published in an international scientific journal cerenoscientific.com ↗
The article is based on Cereno's first clinical study with its drug candidate CS1, which was concluded last year with positive results regarding safety, pharmacokinetic properties and effect on biomarker (PAI-1). |
| 2019-05-24 | Cereno Scientific AB | Results Cereno Scientific identifies possibilities for expanding the use of its treatment concept in cardiovascular diseases cerenoscientific.com ↗
A newly published article (Scholtz et al., 2019) from a research group in Germany showed that valproic acid, the active substance in CS1, prevents atrial fibrillation in mice through slowing the progression of fibrosis in the atria. |
| 2016-10-10 | Cereno Scientific AB | Results Positive data published in Journal of Thrombosis and Haemostasis (JTH) cerenoscientific.com ↗
A paper entitled “Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse” has been published online ahead of print in JTH. |
All press releases naming this drug 14 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 112 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | valproate | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗69“Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or...” NCT00159588 ↗ “An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).” NCT00857584 ↗ “Part 2 - DDI with valproate (valproic acid [VPA]), a probe substrate for β-oxidation and glucuronidation.” NCT06930872 ↗ “a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)” NCT06549426 ↗ “Valproate (according to response, serum levels, and tolerance) 125-2000mg” NCT01000402 ↗ “carbamazepine, valproate, oxcarbazepine or levetiracetam” NCT03490487 ↗ “Choose lithium or valproate for bipolar disorder group” NCT04218981 ↗ “Ethosuximide, valproate or lamotrigine” NCT04274179 ↗ |
| Known as | DEP | “Sodium Valproate (Depakote, DEP) or placebo (PLA) group” NCT02011750 ↗ |
| Known as | Depacon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00203242 ↗ |
| Known as | Depakine | “Depakine (VPA)” NCT04940572 ↗ |
| Known as | Depakine chrono | “treatment by VPA (Depakine chrono)” NCT04940572 ↗ |
| Known as | Depakote | “Depakote (valproate)” NCT00552500 ↗ |
| Known as | divalproex | “This prospective, 12-week open label study evaluated adjunct extended-release valproate semisodium (divalproex) in 20 older adults with schizophrenia.” PMID 17582828 ↗ Feb 2008 |
| Known as | divalproex sodium | “We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate).” PMID 21810649 ↗ Aug 2011 |
| Known as | magnesium valproate | “Patients received hydralazine at 182 mg for rapid, or 83 mg for slow, acetylators, and magnesium valproate at 40 mg/kg, beginning a week before chemotherapy.” PMID 17761710 ↗ Sep 20071“magnesium valproate at an oral dose of 40mg/Kg t.i.d.” NCT00533299 ↗ |
| Known as | sodium valproate | “Anyone of Valproic acid, sodium valproate, or a mixture of the two (sodium valproate) has a mechanism of action characterized by increasing or improving GABA neurotransmission,...” NCT04698525 ↗38“Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗ “extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy.” PMID 27552848 ↗ Aug 2016 “Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)” NCT02556320 ↗ “ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.” NCT02899611 ↗ “Subjects in group C began to receive sodium valproate sustained-release tablets in combination with the original treatment regimen at week 5.” NCT05481957 ↗ “CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule.” NCT05224531 ↗ “Initially 10-15 mg of sodium valproate/kg bodyweight per day will be taken in one or two doses during meals.” NCT04940572 ↗ “Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate” NCT03616223 ↗ “Sodium valproate tablet 200mg” NCT00742638 ↗ “Sodium Valproate” NCT02205931 ↗ |
| Known as | Valproate Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04698525 ↗ |
| Known as | valproic acid | “For children with cryptogenic generalized epileptic disorders, the AED sodium valproate (valproic acid) has been found to be often effective, has fewer side effects than many...” NCT01730313 ↗2“Valproate (valproic acid), a widely used antiepileptic and mood-stabilizing agent, is also a histone deacetylase (HDAC) inhibitor” NCT07226141 ↗ “Part 2 - DDI with valproate (valproic acid [VPA]), a probe substrate for β-oxidation and glucuronidation.” NCT06930872 ↗ |
| Known as | VPA | “Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen,...” NCT00367874 ↗4“Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.” NCT00774306 ↗ “Sodium valproate (VPA) is a first-line prescription drug widely used in the treatment of epilepsy.” NCT07046676 ↗ “ZYN002 (transdermal), VPA (oral)” NCT06930872 ↗ “Depakine (VPA)” NCT04940572 ↗ |
| Known as | VPA-ER | “extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy.” PMID 27552848 ↗ Aug 2016 |
| Action | Inhibit | “a histone deacetylase inhibitor” PMID 19743466 ↗ Aug 2009 |
| Modality | Small molecule | “Valproate, a short chain fatty acid histone deacetylase inhibitor has been shown to increase the protein level of SMN2” NCT01671384 ↗ |
| Route | Intravenous | “On day 1, the experimental group receives a loading dose of valproate sodium intravenously over 1 hour within 24 hours of injury.” NCT00004817 ↗ |
| Target | SMN2 | “Drugs such as valproic acid, phenylbutyrate, and sodium butyrate that mainly act as histone deacetylase inhibitors can mediate both: they stimulate the SMN2 gene transcription” NCT01671384 ↗ |